Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

AstraZeneca

ClinicalTrials.gov Identifier:

NCT01308372

First received: February 18, 2011

Last updated: November 4, 2011

Last verified: November 2011

History of Changes

Purpose

The purpose of this study is to evaluate the proportion of patients which present a high cardiovascular risk estimated by the SCORE scale, in general practice consultations of the 7 French regions (Paris area, North-East, Paris basin, West, South-West, South- East, Mediterranean area)

Condition
Healthy

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Cross-Sectional
Official Title:	Cardiovascular Risk in General Practice in France

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Evaluation of cardiovascular risk in general practice in France estimated by the SCORE scale [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 2008 scale D'Agostino [ Time Frame: 1 week ] [ Designated as safety issue: No ]
Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 1998 scale Wilson [ Time Frame: 1 week ] [ Designated as safety issue: No ]
Evaluation of arteries age evaluation by SCORE [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Enrollment:	9246
Study Start Date:	October 2011
Study Completion Date:	October 2011
Primary Completion Date:	October 2011 (Final data collection date for primary outcome measure)

Groups/Cohorts
1 For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;

Detailed Description:

MC MD

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Primary care

Criteria

Inclusion Criteria:

Without any personal history of coronary disease
Non treated with lipid-lowering agents
Lipid test = 1 year old
Presenting at least one cardiovascular risk
Visiting their General Practitioner

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01308372

Show 587 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:	Eric BRUCKERT, Pr.	Hôpital Pitié-Salpétrière - Service Endocrinologie-Métabolisme
Principal Investigator:	Jean DALLONGEVILLE, Dr.	Institut Pasteur de Lille - Unité d'Epidémiologie et de santé publique Inserm UMR 744
Principal Investigator:	Jean FERRIERES, Pr.	CHU Rangueil - Service de Cardiologie B - Toulouse
Principal Investigator:	Serge KOWNATOR, Dr.	Thionville -Société Française de Cardiologie

More Information

No publications provided

Responsible Party:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT01308372 History of Changes
Other Study ID Numbers:	NIS-CFR-XXX-2011/1
Study First Received:	February 18, 2011
Last Updated:	November 4, 2011
Health Authority:	France: French Data Protection Authority

Keywords provided by AstraZeneca:

cardiovascular risk
France
General practice
Primary prevention
Non treated patients

ClinicalTrials.gov processed this record on May 23, 2013

To Top